Domestic: | 1-888-886-7786 |
International: | 1-416-764-8658 |
Conference ID: | 27947513 |
Webcast: | Link |
Participants can use the dial-in information above or choose the Call me™ option (click here) for instant telephone access to the event which will be made active 15 minutes prior to the scheduled start time. A live webcast or replay of the conference call may be found here or on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
Source:
2024 GlobeNewswire, Inc., source